Absence of neural modulation of hypoxic pulmonary vasoconstriction in conscious dogs.
Our objectives were 1) to quantify the magnitude of the hypoxic pulmonary vasoconstrictor (HPV) response in conscious dogs by utilizing pulmonary vascular pressure-cardiac index (P/Q) plots and 2) to assess the extent to which the autonomic nervous system (ANS) modulates the HPV response. Multipoint P/Q plots were constructed in conscious dogs during normoxia and during bilateral alveolar hypoxia by stepwise constriction of the thoracic inferior vena cava to reduce Q. With the ANS intact, the pulmonary vascular pressure gradient (pulmonary arterial pressure-pulmonary capillary wedge pressure) increased (P less than 0.01) approximately twofold during hypoxia over a broad range of Q. The absolute magnitude of the HPV response was related (P less than 0.01) to the level of Q. We hypothesized that if ANS activation reduces the magnitude of HPV in intact dogs, then we would expect the magnitude of HPV to be increased both after combined sympathetic alpha-(phentolamine) and beta-(propranolol) adrenergic block and after total autonomic ganglionic block (hexamethonium). A marked HPV response (P less than 0.01) was observed after both combined sympathetic block and ganglionic block over a broad range of Q during alveolar hypoxia. The magnitude of the HPV response with the ANS intact, however, was not significantly different from the magnitude of HPV after combined sympathetic block (P = 0.45) or after ganglionic block (P = 0.64) at any level of Q. Thus, during bilateral alveolar hypoxia, the ANS does not appear to attenuate the HPV response of intact conscious dogs.
D000818:Animals; D001341:Autonomic Nervous System / Q000503:physiopathology*; D001794:Blood Pressure; D001835:Body Weight; D002302:Cardiac Output; D003250:Constriction; D004285:Dogs; D005728:Ganglia, Sympathetic / Q000187:drug effects / Q000503:physiopathology; D018738:Hexamethonium; D006584:Hexamethonium Compounds / Q000494:pharmacology; D000860:Hypoxia / Q000503:physiopathology*; D008168:Lung / Q000098:blood supply*; D008297:Male; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000502:physiology; D011943:Receptors, Adrenergic, beta / Q000187:drug effects / Q000502:physiology; D014661:Vasoconstriction; D014682:Vena Cava, Inferior
D006584:Hexamethonium Compounds; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D018738:Hexamethonium; D011433:Propranolol; D010646:Phentolamine